Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers

Journal of Psychopharmacology

Volumn 28, Issue 6, 2014, Pages 596-602

  Van Ameringen, Michael ^a   Simpson, William ^a,b   Patterson, Beth ^a   Dell'Osso, Bernardo ^c   Fineberg, Naomi ^d,o   Hollander, Eric ^e   Hranov, Luchezar ^f   Hranov, Georgi ^f   Lochner, Christine ^g   Karamustafalioglu, Oguz ^h   Marazziti, Donatella ⁱ   Menchon, Jose M ^j   Nicolini, Humberto ^k   Pallanti, Stefano ^l   Stein, Dan J ^m   Zohar, Joseph ⁿ  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h SiAYli Etfal Teaching and Research Hospital of Istanbul   (Turkey)

ⁱ UNIVERSITY OF PISA   (Italy)

^j UNIVERSITY OF BARCELONA   (Spain)

^k UNIVERSIDAD AUTÓNOMA DE LA CIUDAD DE MÉXICO   (Mexico)

^l UNIVERSITY OF FLORENCE   (Italy)

^m UNIVERSITY OF CAPE TOWN   (South Africa)

ⁿ SHEBA MEDICAL CENTER   (Israel)

^o UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

more..

Author keywords

augmentation; effectiveness; international; medication; Obsessive compulsive disorder; treatment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SELF REPORT; STRUCTURED INTERVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; EUROPE; HEALTH CARE DISPARITY; HEALTH CARE SURVEY; ISRAEL; MIDDLE AGED; MULTICENTER STUDY; NORTH AMERICA; PROTOCOL COMPLIANCE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HUMANS; ISRAEL; MALE; MIDDLE AGED; NORTH AMERICA; OBSESSIVE-COMPULSIVE DISORDER; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84901608080     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113517955     Document Type: Article

References (50)

1. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review. J Consult Clin Psychol. 1997 ; 65: 44-52
2. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs. 2011 ; 25: 585-596
3. Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-Acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012 ; 32: 797-803
4. Baer L, Jenike MA. Personality disorders in obsessive compulsive disorder. Psychiatr Clin N Am. 1992 ; 15: 803-808
5. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 ; 19: 567-596
6. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008 ; 9: 248-312
7. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011 ; 72: 716-721
8. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010 ; 15: 850-855
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006 ; 11: 622-632
10. Bobes J, Gonzalez MP, Bascaran MT, et al. Quality of life and disability in patients with obsessive-compulsive disorder. Eur Psychiatry. 2001 ; 16: 239-245
11. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol. 2002 ; 12: 181-186
12. Clinical practice guidelines management of anxiety disorders. C J Psychiatry. 2006 ; 51: 9S - 91S
13. Carrasco JL, Hollander E, Schneier FR, et al. Treatment outcome of obsessive compulsive disorder with comorbid social phobia. J Clin Psychiatry. 1992 ; 53: 387-391
14. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry. 2005 ; 58: 424-428
15. Denys D, Burger H, van Megen H, et al. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2003 ; 18: 315-322
16. duc Toit PL, van Kradenburg J, Niehaus D, et al. Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. Compr Psychiatry. 2001 ; 42: 291-300
17. Eisen JL, Mancebo MA, Pinto A, et al. Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006 ; 47: 270-275
18. Fineberg N, Reghunandanan S, Brown A, et al. Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond. Aus NZ J Psychiatry. 2013 ; 47: 121-141
19. Fineberg NA, Craig KJ. Pharmacological treatment for obsessive-compulsive disorder. Psychiatry. 2007 ; 6: 234-239
20. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. In J Neuropsychopharmacol. 2005 ; 8: 107-129
21. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005 ; 162: 151-161
22. Foa EB, Simpson HB, Liebowitz MR, et al. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry. 2013 ; 74: 464-469
23. Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013 ; 47: 175-180
24. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989 1006 ; 46 :
25. Guy W ECDEU Assessment Manual for Psychopharmacology - Revised. Rockville, MD: US Department of Health ; 1976 :
26. Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 ; 64: 640-647
27. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006 ; 4: 005473
28. Komossa K, Depping AM, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010 ; 12: 008141
29. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin N Am. 2000 ; 23: 509-517
30. Koran LM, Hanna GL, Hollander E, et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007 ; 164: 5-53
31. McDougle CJ, Goodman WK, Leckman JF, et al. The efficacy of fluvoxamine in obsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993 ; 13: 354-358
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 ; 134: 382-389
33. Mowla A, Khajeian AM, Sahraian A, et al. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr. 2010 ; 15: 613-617
34. National Center for Biotechnology Information (2012) PubMed Drug & Supplements Monograph Citalopram.
35. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial. J Clin Psychiatry. 2006 ; 67: 15-22
36. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: Management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2004 ; 65: 6-10
37. Pampaloni I, Sivakumaran T, Hawley C, et al. High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. J Psychopharmacol. 2010 ; 24: 1439-1445
38. Rapaport MH, Clary C, Fayyad R, et al. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005 ; 162: 1171-1178
39. Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, et al. Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clin Psychol Rev. 2008 ; 28: 1310-1325
40. Rosario-Campos M, Miguel E, Quatrano S, et al. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): An instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry. 2006 ; 11: 495-504
41. Rubio G, Jimenez-Arriero MA, Martinez-Gras I, et al. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006 ; 26: 341-344
42. Sheehan DV The Anxiety Disease. New York: Scribner ; 1983 :
43. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998 ; 59: 22-33
44. Simpson HB, Huppert JD, Petkova E, et al. Response versus remission in obsessive compulsive disorder. J Clin Psychiatry. 2006 ; 67: 269-276
45. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: A meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007 ; 17: 79-93
46. Stein D, Montgomery S, Kasper S, et al. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001 ; 16: 357-361
47. Stein DJ, Koen N, Fineberg N, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep. 2012 ; 14: 211-219
48. Steiner M, Gergel I, Wheadon D.. Annual Meeting of the American Psychiatric Association ; 1996 New York ; 1996..
49. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: A retrospective, open-label case series. Depress Anxiety. 2006 ; 23: 1-5
50. Van Balkom A, van Oppen P, Vermeulen A, et al. A meta-analysis on the treatment of obsessive-compulsive disorder: A comparison of antidepressants, behaviour, and cognitive therapy. Clin Psychol Rev. 1994 ; 14: 359-381